A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)

被引：0

作者：

Weinblatt, Michael E. ^{[1
]}

Baranauskaite, Asta ^{[2
]}

Niebrzydowski, Jaroslaw ^{[3
]}

Dokoupilova, Eva ^{[4
]}

Zielinska, Agnieszka ^{[5
]}

Sitek-Ziolkowska, Karina ^{[6
]}

Jaworski, Janusz ^{[7
]}

Racewicz, Artur ^{[8
]}

Pileckyte, Margarita ^{[2
]}

Jedrychowicz-Rosiak, Krystyna ^{[9
]}

Zhdan, Vyacheslav ^{[10
]}

Cheong, Soo Yeon ^{[11
]}

Ghil, Jeehoon ^{[11
]}

机构：

[1] Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Lithuanian Univ Hlth Sci, Kaunas, Lithuania

[3] Med Pro Familia, Gdynia, Poland

[4] Med Plus Sro, Uherske Hradiste, Czech Republic

[5] Med Pro Familia, Warsaw, Poland

[6] Med Pro Familia, Katowice, Poland

[7] Reumatika Ctr Reumatol, Warsaw, Poland

[8] Zdrowie Osteomed Sc, Bialystok, Poland

[9] Mazowieckie Ctr Badan Klin, Grodzisk Mazowiecki, Poland

[10] MV Sklifosovskyi Poltava Reg Clin Hosp, Poltava, Ukraine

[11] Samsung Bioepis Co Ltd, Inchon, South Korea

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] SECONDARY EFFICACY RESULTS UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMIAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
Kay, J.
Weinblatt, M.
Keystone, E.
Genovese, M. C.
Baranauskaite, A.
Cheong, S. Y.
Ghil, J.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 231 - 231
[2] Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Weinblatt, Michael E.
Baranauskaite, Asta
Niebrzydowski, Jaroslaw
Dokoupilova, Eva
Zielinska, Agnieszka
Jaworski, Janusz
Racewicz, Artur
Pileckyte, Margarita
Jedrychowicz-Rosiak, Krystyna
Cheong, Soo Yeon
Ghil, Jeehoon
ARTHRITIS & RHEUMATOLOGY, 2018, 70 (01) : 40 - 48
[3] IMPACT OF ANTI-DRUG ANTIBODIES ON EFFICACY AND SAFETY UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
Genovese, M. C.
Weinblatt, M.
Keystone, E.
Baranauskaite, A.
Cheong, S. Y.
Ghil, J.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 234 - 234
[4] A PHASE III RANDOMISED, DOUBLE-BLIND CLINICAL STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, WITH ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY (24-WEEK RESULTS)
Vencovsky, J.
Sylwestrzak, A.
Leszczynski, P.
Porawska, W.
Baranauskaite, A.
Tseluyko, V.
Zhdan, V.
Stasiuk, B.
Milasiene, R.
Rodriguez, A. A. Barrera
Cheong, S. Y.
Ghil, J.
Emery, P.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 467 - 468
[5] Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
Genovese, Mark
Weinblatt, Michael
Keystone, Edward
Baranauskaite, Asta
Cheong, Soo-Yeon
Ghil, Jeehoon
JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 878 - 878
[6] Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
Weinblatt, Michael E.
Baranauskaite, Asta
Dokoupilova, Eva
Zielinska, Agnieszka
Jaworski, Janusz
Racewicz, Artur
Pileckyte, Margarita
Jedrychowicz-Rosiak, Krystyna
Baek, Inyoung
Ghil, Jeehoon
ARTHRITIS & RHEUMATOLOGY, 2018, 70 (06) : 832 - 840
[7] A PHASE I PHARMACOKINETIC STUDY COMPARING SB5, AN ADALIMUMAB BIOSIMILAR, AND ADALIMUMAB REFERENCE PRODUCT (HUMIRA®) IN HEALTHY SUBJECTS
Shin, D.
Kim, Y.
Kim, H. S.
Fuhr, R.
Kornicke, T.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 459 - 460
[8] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)
Vencovsky, Jiri
Sylwestrzak, Anna
Leszczynski, Piotr
Porawska, Wieslawa
Baranauskaite, Asta
Tseluyko, Vira
Zhdan, Vyacheslav
Stasiuk, Barbara
Milasiene, Roma
Barrera Rodriguez, Aaron Alejandro
Cheong, Soo Yeon
Ghil, Jeehoon
Emery, Paul
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[9] A Randomized, Double-Blind, Phase III Study Comparing SB2, an Infliximab Biosimilar, to the Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week Results
Choe, Jung-Yoon
Prodanovic, Nenad
Niebrzydowski, Jaroslaw
Staykov, Ivan
Dokoupilova, Eva
Baranauskaite, Asta
Yatsyshyn, Roman
Mekic, Mevludin
Porawska, Wieslawa
Ciferska, Hana
Jedrychowicz-Rosiak, Krystyna
Zielinska, Agnieszka
Choi, Jasmine
Rho, Young Hee
Smolen, Josef S.
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[10] Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study
Weinblatt, Michael
Baranauskaite, Asta
Niebrzydowski, Jaroslaw
Dokoupilova, Eva
Zielinska, Agnieszka
Sitek-Ziolkowska, Karina
Jaworski, Janusz
Racewicz, Artur
Pileckyte, Margarita
Jedrychowicz-Rosiak, Krystyna
Zhdan, Vyacheslav
Cheong, Soo Yeon
Ghil, Jeehoon
ARTHRITIS & RHEUMATOLOGY, 2016, 68

← 1 2 3 4 5 →